GoodRx Holdings, Inc. (GDRX) Tops Q1 EPS by 2c, Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
GoodRx Holdings Inc. (GDRX) PT Lowered to $12 at Goldman Sachs
May 10, 2022 7:00 AM EDTGoldman Sachs analyst Eric Sheridan lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $12.00 (from $30.00) while maintaining a Buy rating.
The analyst commented, "In its Q1 22 earnings report, GoodRx presented a solid quarterly report but framed the forward business trajectory as impacted by a "grocer" partner that had... More
